Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 19/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.77 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | HTR3A | P46098 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13281963 | 0.88 | ADORA3 (0.79) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12805033 | 0.87 | ADORA3 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573571 | 0.87 | ADORA3 (0.88) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573308 | 0.86 | ADORA3 (0.78) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12804687 | 0.86 | ADORA1 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574523 | 0.86 | ADORA3 (0.76) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12805145 | 0.85 | ADORA3 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12805349 | 0.85 | ADORA3 (0.73) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12805428 | 0.84 | ADORA3 (1.00) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574063 | 0.84 | ADORA3 (0.73) | ADORA3ADORA1ADORA2ATMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181253-B2 | Adenosine receptor agonists, partial agonists, and antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120252823-A1 | ADENOSINE RECEPTOR AGONISTS, PARTIAL AGONISTS, AND ANTAGONISTS | SERVICES (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252823-A1 | ADENOSINE RECEPTOR AGONISTS, PARTIAL AGONISTS, AND ANTAGONISTS | ADORA1, ADORA3, ADORA2A | ADORA3 2/4885ADORA1 1/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.